SCHEMBL8444737

SCHEMBL8444737

O=C(N1CCC(CCSc2ccccc2)CC1)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.48
▸ RAB9A P51151 5/20 0.48
▸ ALDH1A1 P00352 4/20 0.48
▸ KDM1A O60341 1/20 0.46
▸ NPC1 O15118 4/20 0.46
▸ TEAD1 P28347 1/20 0.44
▸ TEAD3 Q99594 1/20 0.44
▸ GRIN2B Q13224 2/20 0.43
▸ RIPK1 Q13546 1/20 0.43
▸ USP2 O75604 1/20 0.43
▸ CHRM2 P08172 3/20 0.43
▸ CHRM1 P11229 3/20 0.43
▸ CHRM3 P20309 3/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ MAPT P10636 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ GRIN2A Q12879 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13913916 0.81 TEAD1 (0.67) RAB9AALDH1A1KDM1ANPC1TEAD1
SCHEMBL8444736 0.78 KDM4E (0.59) SMN1; SMN2RAB9AALDH1A1NPC1MAPT
SCHEMBL4773959 0.77 KDM1A (0.53) SMN1; SMN2RAB9AALDH1A1KDM1ARIPK1
SCHEMBL4768006 0.77 CYP2C9 (0.64) RAB9AMEN1KMT2AGAACYP2C9
SCHEMBL7875061 0.76 CHRM4 (0.51) SMN1; SMN2RAB9AALDH1A1NPC1TEAD1
SCHEMBL22558220 0.74 ALDH1A1 (0.44) SMN1; SMN2RAB9AALDH1A1NPC1TEAD1
SCHEMBL7850437 0.72 GPR119 (0.46) RAB9ANPC1
SCHEMBL571141 0.72 KDM1A (0.60) SMN1; SMN2RAB9AALDH1A1KDM1ANPC1
SCHEMBL7874834 0.71 GRIN2B (0.61) ALDH1A1GRIN2BGRIN2A
SCHEMBL7477572 0.71 EPHX1 (0.45) KDM1ANPC1RIPK1CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070117847-A1 N-(3-(4-Substituted-1-piperiding1)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists CHAMBERS MARK S 2007-05-24 — — US disclosed
US-20040002504-A1 N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists MERCK SHARP & DOHME LTD. (GB) 2004-01-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002504-A1 N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists KCNH3, KCNH2, KCNK3 SMN1; SMN2 2687/4885RAB9A 1554/4885ALDH1A1 2125/4885
US-20070117847-A1 N-(3-(4-Substituted-1-piperiding1)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists TACR2, KCNK3, KCNH3 SMN1; SMN2 2466/4885RAB9A 1359/4885ALDH1A1 1775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback